Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema. Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.
Level 2/517 Flinders Ln, Melbourne VIC 3000, Australia
The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.